Bio-Techne (TECH) financial statements
Bio-Techne reported revenue of $1.2B in fiscal 2026, up 8.9% a year over 9 years.
Net income was $182M and the operating margin 20.7%, against 21.4% in 2017.
Free cash flow was $263M, and the company returned $50M in dividends and $42M in net buybacks.
The diluted share count rose 5% over the period (dilution).
Revenue and free cash flow
Fiscal years, $ billions.
Income statement
Fiscal years, from Bio-Techne's 10-K filings with the SEC.
| Fiscal year | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $563M | $643M | $714M | $739M | $931M | $1.1B | $1.1B | $1.2B | $1.2B | $1.2B |
| Cost of revenue | $188M | $211M | $241M | $255M | $298M | $349M | $367M | $389M | $429M | $416M |
| Gross profit | $375M | $432M | $473M | $483M | $633M | $756M | $770M | $770M | $790M | $799M |
| Research and development | $54M | $55M | $62M | $65M | $71M | $87M | $92M | $97M | $99M | $95M |
| Selling, general and admin | $200M | $241M | $264M | $261M | $325M | $373M | $378M | $466M | $589M | $452M |
| Operating income | $121M | $136M | $147M | $157M | $237M | $297M | $299M | $207M | $102M | $252M |
| Interest expense | $7M | $10M | $22M | $19M | $14M | $11M | $11M | $16M | $9M | $10M |
| Pre-tax income | $112M | $126M | $112M | $276M | $148M | $301M | $339M | $186M | $98M | $241M |
| Income tax | $36M | -$198,000 | $16M | $47M | $9M | $38M | $53M | $18M | $25M | $59M |
| Net income | $76M | $126M | $96M | $229M | $140M | $272M | $285M | $168M | $73M | $182M |
| EPS (diluted) | $0.51 | $0.83 | $0.62 | $1.46 | $0.87 | $1.66 | $1.76 | $1.05 | $0.46 | $1.16 |
| Diluted shares | 150M | 152M | 156M | 158M | 162M | 164M | 162M | 161M | 160M | 157M |
| Gross margin | 66.5% | 67.2% | 66.3% | 65.4% | 68.0% | 68.4% | 67.7% | 66.4% | 64.8% | 65.8% |
| Operating margin | 21.4% | 21.2% | 20.5% | 21.3% | 25.5% | 26.8% | 26.3% | 17.8% | 8.4% | 20.7% |
| Net margin | 13.5% | 19.6% | 13.5% | 31.0% | 15.1% | 24.6% | 25.1% | 14.5% | 6.0% | 15.0% |
Balance sheet
Fiscal years, from Bio-Techne's 10-K filings with the SEC.
| Fiscal year | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and short-term investments | $158M | $182M | $166M | $271M | $232M | $247M | $204M | $153M | $162M | $265M |
| Receivables | $117M | $120M | $137M | $123M | $145M | $195M | $218M | $241M | $207M | $217M |
| Inventory | $86M | $86M | $91M | $103M | $117M | $141M | $172M | $180M | $189M | $196M |
| Total current assets | $348M | $398M | $413M | $521M | $511M | $606M | $621M | $617M | $608M | $744M |
| Property, plant and equipment | $135M | $145M | $154M | $177M | $208M | $223M | $226M | $251M | $246M | $232M |
| Goodwill | $579M | $598M | $733M | $728M | $843M | $822M | $873M | $973M | $981M | $975M |
| Total assets | $1.6B | $1.6B | $1.9B | $2.0B | $2.3B | $2.3B | $2.6B | $2.7B | $2.6B | $2.6B |
| Total current liabilities | $136M | $80M | $102M | $107M | $152M | $176M | $129M | $159M | $176M | $164M |
| Long-term debt | $344M | $339M | $493M | $344M | $329M | $243M | $350M | $319M | $346M | $200M |
| Total liabilities | $609M | $514M | $719M | $646M | $692M | $594M | $672M | $635M | $639M | $479M |
| Shareholders' equity | $950M | $1.1B | $1.2B | $1.4B | $1.6B | $1.7B | $2.0B | $2.1B | $1.9B | $2.1B |
| Net debt | $252M | $217M | $404M | $210M | $142M | $83M | $169M | $167M | $184M | -$65M |
Cash flow
Fiscal years, from Bio-Techne's 10-K filings with the SEC.
| Fiscal year | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $144M | $170M | $182M | $205M | $352M | $325M | $254M | $299M | $288M | $292M |
| Capital spending | $15M | $21M | $25M | $52M | $44M | $45M | $38M | $63M | $31M | $29M |
| Free cash flow | $129M | $149M | $156M | $153M | $308M | $280M | $216M | $236M | $257M | $263M |
| Stock-based compensation | $15M | $28M | $32M | $32M | $49M | $42M | $39M | $38M | $41M | $41M |
| Dividends paid | $47M | $48M | $48M | $49M | $50M | $50M | $50M | $50M | $50M | $50M |
| Share buybacks (net) | — | $0 | -$15M | -$50M | -$43M | -$161M | -$20M | -$80M | -$276M | -$42M |
| Free cash flow margin | 22.8% | 23.2% | 21.9% | 20.8% | 33.1% | 25.4% | 19.0% | 20.4% | 21.0% | 21.7% |
| Dividends per share | $0.32 | $0.32 | $0.31 | $0.31 | $0.31 | $0.31 | $0.31 | $0.31 | $0.32 | $0.32 |
Questions
What was Bio-Techne's revenue in 2026?
$1.2B in fiscal 2026, from its 10-K filing.
How much free cash flow does Bio-Techne generate?
$263M in fiscal 2026 (operating cash flow minus capital spending).
From Bio-Techne's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.